Evidence map›Paper›PMID 25984363›Full record

ReviewJournal of thoracic disease2015

Multidisciplinary management of advanced lung neuroendocrine tumors.

Pier Luigi Filosso, Piero Ferolla, Francesco Guerrera, Enrico Ruffini, William D Travis, Giulio Rossi, Paolo Olivo Lausi, Alberto Oliaro, European Society of Thoracic Surgeons Lung Neuroendocrine Tumors Working-Group Steering Committee

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of thoracic disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature.European respiratory review : an official journal of the European Respiratory Society · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Anatomical resections are superior to wedge resections for overall survival in patients with Stage 1 typical carcinoids.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2019
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Pier Luigi Filosso1 Department of Thoracic Surgery, University of Torino Italy, Torino, Italy ; 2 Multidisciplinar Group for Diagnosis and Therapy of Neuroendocrine Tumors, Umbria Regional Cancer Network, Orbassano, Italy ; 3 Department of Pathology Memorial Sloan Kettering Cancer Center, New York, USA ; 4 Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy ; 5 The European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumors of the Lung Working-Group Steering Committee.
Piero Ferolla1 Department of Thoracic Surgery, University of Torino Italy, Torino, Italy ; 2 Multidisciplinar Group for Diagnosis and Therapy of Neuroendocrine Tumors, Umbria Regional Cancer Network, Orbassano, Italy ; 3 Department of Pathology Memorial Sloan Kettering Cancer Center, New York, USA ; 4 Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy ; 5 The European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumors of the Lung Working-Group Steering Committee.
Francesco Guerrera1 Department of Thoracic Surgery, University of Torino Italy, Torino, Italy ; 2 Multidisciplinar Group for Diagnosis and Therapy of Neuroendocrine Tumors, Umbria Regional Cancer Network, Orbassano, Italy ; 3 Department of Pathology Memorial Sloan Kettering Cancer Center, New York, USA ; 4 Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy ; 5 The European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumors of the Lung Working-Group Steering Committee.
Enrico Ruffini1 Department of Thoracic Surgery, University of Torino Italy, Torino, Italy ; 2 Multidisciplinar Group for Diagnosis and Therapy of Neuroendocrine Tumors, Umbria Regional Cancer Network, Orbassano, Italy ; 3 Department of Pathology Memorial Sloan Kettering Cancer Center, New York, USA ; 4 Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy ; 5 The European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumors of the Lung Working-Group Steering Committee.
William D Travis1 Department of Thoracic Surgery, University of Torino Italy, Torino, Italy ; 2 Multidisciplinar Group for Diagnosis and Therapy of Neuroendocrine Tumors, Umbria Regional Cancer Network, Orbassano, Italy ; 3 Department of Pathology Memorial Sloan Kettering Cancer Center, New York, USA ; 4 Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy ; 5 The European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumors of the Lung Working-Group Steering Committee.
Giulio Rossi1 Department of Thoracic Surgery, University of Torino Italy, Torino, Italy ; 2 Multidisciplinar Group for Diagnosis and Therapy of Neuroendocrine Tumors, Umbria Regional Cancer Network, Orbassano, Italy ; 3 Department of Pathology Memorial Sloan Kettering Cancer Center, New York, USA ; 4 Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy ; 5 The European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumors of the Lung Working-Group Steering Committee.
Paolo Olivo Lausi1 Department of Thoracic Surgery, University of Torino Italy, Torino, Italy ; 2 Multidisciplinar Group for Diagnosis and Therapy of Neuroendocrine Tumors, Umbria Regional Cancer Network, Orbassano, Italy ; 3 Department of Pathology Memorial Sloan Kettering Cancer Center, New York, USA ; 4 Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy ; 5 The European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumors of the Lung Working-Group Steering Committee.
Alberto Oliaro1 Department of Thoracic Surgery, University of Torino Italy, Torino, Italy ; 2 Multidisciplinar Group for Diagnosis and Therapy of Neuroendocrine Tumors, Umbria Regional Cancer Network, Orbassano, Italy ; 3 Department of Pathology Memorial Sloan Kettering Cancer Center, New York, USA ; 4 Unit of Pathology, Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy ; 5 The European Society of Thoracic Surgeons (ESTS) Neuroendocrine Tumors of the Lung Working-Group Steering Committee.
European Society of Thoracic Surgeons Lung Neuroendocrine Tumors Working-Group Steering Committee
European Neuroendocrine Tumor Society · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal clinical management of aggressive/advanced lung neuroendocrine tumors (NETs) is still debated, due to their rarity and the lack of prospective randomized studies. Results derive from retrospective mono-Institutional series, and few dedicated prospective trials, recently designed, are still ongoing. In low-grade tumors [bronchial carcinoids (BCs)] surgery, whenever feasible, remains the mainstay of treatment, and chemo/radiotherapy (RT) should be reserved to progressive diseases (PD). In case of resected N1-N2 BCs, a "watch and see" policy associated with a close clinical/radiological follow-up is recommended. Somatostatin analogs (SSA) seem to be effective in controlling BCs associated endocrine syndromes, while SSA antiproliferative effect has also been reported in the past. Targeted therapy with new drugs (Everolimus) seems to be very promising, but further trials are needed. Surgery alone is not sufficient to treat high-grade NETs: adjuvant CT is required also in early stages. Platinum-Etoposide regimen demonstrated to be the most effective; irinotecan and other biological drugs are considered very promising. In conclusion, the management of advanced lung NETs should be individualized by multidisciplinary teams which include Medical and Radiation Oncologists, Surgeons, Pathologists, Pulmonologists, Endocrinologists, Interventional Radiologists, and the prognosis is mainly dependent on tumor grade and its anatomical extent.

Indexed as

biological therapychemotherapyLungmetastasesneuroendocrine tumors (NETs)radiotherapy (RT)recurrencesurgerysurvival

Identifiers

PMID25984363
PMCPMC4419025
OpenAlexW1915041501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.